![James Daly](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 3 M $ in data 31/05/2026
James M.
Daly currently serves as Independent Director at ACADIA Pharmaceuticals, Inc. since 2016, Independent Non-Executive Director at argenx SE since 2018, Independent Director at Madrigal Pharmaceuticals, Inc. since 2019, and Independent Director at Cytokinetics, Inc. starting in 2025.
Former roles include Independent Director at Halozyme Therapeutics, Inc. from 2015 to 2023, Independent Director at Chimerix, Inc. from 2014 to 2020, Independent Director at Bellicum Pharmaceuticals, Inc. from 2016 to 2024, Director at Coherus Oncology, Inc., Senior Vice President-Global Marketing & Commercial Development at Amgen, Inc. from 2002 to 2011, Chief Commercial Officer & Executive Vice President at Incyte Corp.
from 2012 to 2015, Senior Vice President at Amgen Ventures LLC, Principal at Francis Cauffman, Inc., and Senior Vice President-Respiratory Division at GlaxoSmithKline LLC from 1985 to 2001.
Education includes an undergraduate degree and an MBA from the State University of New York at Buffalo, conferred in 1983 and 1985 respectively.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 17/06/2026 | 3.081 ( 0,01% ) | 2 M $ | 31/05/2026 | |
| 19/02/2026 | 1.365 ( 0% ) | 1 M $ | 31/05/2026 | |
| 29/05/2026 | 12.148 ( 0,01% ) | 263 126 $ | 31/05/2026 | |
| 27/05/2026 | 3.239 ( 0% ) | 248 626 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ACADIA PHARMACEUTICALS INC. | Direttore/Membro del Consiglio | 11/01/2016 |
| ARGENX SE | Direttore/Membro del Consiglio | 08/05/2018 |
| MADRIGAL PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 27/06/2019 |
| CYTOKINETICS, INCORPORATED | Direttore/Membro del Consiglio | 19/08/2025 |
| Società | Posizione | Fine |
|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 23/02/2024 |
| HALOZYME THERAPEUTICS, INC. | Direttore/Membro del Consiglio | 31/12/2023 |
| CHIMERIX, INC. | Direttore/Membro del Consiglio | 21/02/2020 |
| INCYTE CORPORATION | Corporate Officer/Principal | 26/06/2015 |
| AMGEN INC. | Corporate Officer/Principal | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 14 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Incyte Corp.
 Incyte Corp. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of proprietary therapeutics | Health Technology |
ACADIA Pharmaceuticals, Inc.
 ACADIA Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals drugs for treatment of central nervous system disorders | Health Technology |
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
Chimerix, Inc.
 Chimerix, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for rare epilepsies, cancers and sleep disorders | Health Technology |
Cytokinetics, Inc.
 Cytokinetics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that discovers, develops and commercializes novel drug products | Health Technology |
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops novel cellular immunotherapies for various forms of cancer | Health Technology |
State University of New York at Buffalo
 State University of New York at Buffalo Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Amgen Ventures LLC
 Amgen Ventures LLC Investment ManagersFinance Amgen Ventures invests in companies located in the United States. The firm focuses on technology and health care sectors. it provides capital for early stage capital requirements. | Finance |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Francis Cauffman, Inc.
 Francis Cauffman, Inc. Engineering & ConstructionIndustrial Services Provides architecture, interior design, and planning services | Industrial Services |
GlaxoSmithKline LLC
 GlaxoSmithKline LLC Pharmaceuticals: MajorHealth Technology Engages in research and development, manufacturing of respiratory, immunology, oncology and infectious disease medicines and vaccines | Health Technology |
Coherus BioSciences, Inc.
 Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
Madrigal Pharmaceuticals, Inc.
 Madrigal Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops small-molecule drugs for cardiovascular, metabolic and liver diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
